APUS

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.04
Percentage change 2.30	%

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.14	Insider Own	82.00%	Shs Outstand	7.90M	Perf Week	3.59%
Market Cap	20.61M	Forward P/E	-	EPS next Y	-	Insider Trans	6.22%	Shs Float	2.08M	Perf Month	-9.18%
Enterprise Value	21.23M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	0.04%	Perf Quarter	-
Income	-1.50M	P/S	-	EPS this Y	-	Inst Trans	0.00%	Short Ratio	0.01	Perf Half Y	-
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-716.40%	Short Interest	0.00M	Perf YTD	-19.09%
Book/sh	-0.22	P/C	82.45	EPS next 5Y	-	ROE	-	52W High	4.00 -55.50%	Perf Year	-
Cash/sh	0.02	P/FCF	-	EPS past 3/5Y	-50.14% -	ROIC	-	52W Low	1.37 29.93%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.59% 9.26%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-75.09%	Oper. Margin	-	ATR (14)	0.18	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.15	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	45.23	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.15	EPS Q/Q	-117.52%	SMA20	-0.44%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-1.17%	Rel Volume	0.13	Prev Close	1.74
Employees	2	LT Debt/Eq	-	Earnings	-	SMA200	-1.17%	Avg Volume	118.69K	Price	1.78
IPO	May 09, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	15,457	Change	2.30%

May-12-25 05:14PM	Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering (GlobeNewswire) -17.73%
May-08-25 05:00PM	Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering (GlobeNewswire)

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. It primarily focuses on developing innovative therapies for inflammation and pain management in knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS). The company was founded on May 11, 2020 and is headquartered in Hopewell, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kim Christopher	Chairman and CMO	May 13 '25	Buy	1.82	19,770	35,981	19,770	May 15 06:48 PM
Kim Christopher	Chairman and CMO	May 14 '25	Buy	1.86	7,730	14,378	27,500	May 15 06:48 PM
Koo Jakap	Director	May 12 '25	Buy	1.99	28,500	56,715	643,885	May 14 05:58 PM
Inscobee Inc.	10% Owner	May 12 '25	Buy	4.00	500,000	2,000,000	1,984,616	May 14 05:52 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Apimeds Pharmaceuticals US Inc

Upgrade your FINVIZ experience